CD4 and AIDS: Phase I/II clinical trials with TCS alone or in combination with other anti-HIV drugs, zidovudine or dideoxinosine, showed that TCS could decrease serum HIV-1 p24 antigen level and increase the percentage of CD4+ cells in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex [65,66].